|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation.
|
31655978 |
2020 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to search for novel TERT promoter mutations and additional mechanisms of TERT activation in thyroid cancer.
|
31408918 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the association between TERT promoter mutations and recurrence in a prospective series of 173 intermediate- to high-risk patients with thyroid cancer.
|
30648628 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Telomerase reverse transcriptase gene analyses greatly facilitate the clinical assessment of follicular thyroid tumors, and pinpoints cases at risk of future recurrences.
|
31131695 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.
|
31024447 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, telomerase reverse transcriptase (<i>TERT</i>) gene promoter (<i>TERTp</i>) mutations (C228T and C250T) were reported at high frequency in TC cell lines and tumor biopsies.
|
31549911 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Somatic telomerase reverse transcriptase (TERT) promoter mutations have been recently identified in several types of malignant tumors, including thyroid neoplasia; however, the actual role of TERT mutations in thyroid tumorigenesis is still under debate.
|
29435002 |
2018 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (<i>TERT</i>) promoter mutations have been linked to adverse clinical parameters in thyroid cancer, but <i>TERT</i>-expressing tumours are not always mutated.
|
29692346 |
2018 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the prevalence and clinical impact of mutations of BRAF, NRAS, HRAS, KRAS, EZH1, EIF1AX, and TERT genes by Sanger sequencing in a series of 201 follicular-patterned thyroid tumors including follicular adenoma (n = 40), Hürthle cell adenoma (n = 54), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (n = 50), follicular thyroid carcinoma (n = 40), Hürthle cell carcinoma (n = 10), and poorly differentiated thyroid carcinoma arising in a well-differentiated follicular neoplasm (n = 7), and 120 classic papillary carcinoma.
|
29723601 |
2018 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telomerase reverse transcriptase (TERT) promoter mutations have recently been identified as an important prognostic factor in thyroid cancer.
|
30102829 |
2018 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, we show for the first time that TERT alterations are associated with familial thyroid tumour progression.
|
28502101 |
2017 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Co-regulation of TERT suggests a mechanism by which allelic variants in/near FOXE1 are associated with thyroid cancer risk.
|
27852061 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The study explored the association between rs10069690C/T and rs2736100G/T of human telomerase reverse transcriptase (hTERT) gene, and the prognosis of thyroid cancer.
|
27472887 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes.
|
26969876 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two mutations (C228T and C250T) in the promoter region of the telomerase reverse transcriptase (TERT) have recently been described in different types of cancer including follicular cell-derived thyroid cancer (TC).
|
26902827 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer.
|
26727717 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests an important role of TERT mutational analysis in the clinical diagnosis and management of thyroid cancer patients.
|
25951319 |
2016 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, this study on a large cohort of TC patients from Middle East demonstrates that TERT promoter mutations are relatively common, especially in the non-CPTC, and are associated with more aggressive histopathological features, BRAF(V600E) mutation, and disease persistence/recurrence than the WT TERT.
|
26354077 |
2015 |
|
Thyroid Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TERT protein was found to be more expressed in neoplastic than in normal tissues, and to display a different cellular localization, suggesting that it could contribute to thyroid cancer progression by mechanisms taking place in the cytoplasm.
|
25448848 |
2015 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two promoter mutations, chr5:1 295 228C>T and chr5:1 295 250C>T, in the gene for telomerase reverse transcriptase (TERT) have been recently identified in thyroid cancers and shown to be important in thyroid tumor pathogenesis.
|
25121551 |
2014 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No TERT mutation was found in 44 benign thyroid tumors.
|
24617711 |
2014 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
CTD_human |
Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types.
|
25383969 |
2014 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objectives of the study were: 1) to determine the prevalence of TERT promoter mutations C228T and C250T in different thyroid cancer histological types and cell lines; and 2) to establish the possible association of TERT mutations with mutations of BRAF, RAS, or RET/PTC.
|
23833040 |
2013 |
|
Thyroid Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A tendency for an inverse correlation between miR-138 and hTERT protein expression was observed in the thyroid cancer cell lines, although this failed to reach significance (r = -0.392, P = 0.148).
|
18201269 |
2008 |